全股骨置换术后植入物翻修与髋关节离断的相关因素:一项回顾性多中心EMSOS研究
该回顾性多中心EMSOS研究纳入1990年1月1日至2024年3月31日期间14个国际中心的143例全股骨置换患者,评估植入物翻修和髋关节离断的累积发生率及相关因素。结果显示2年和5年植入物翻修累积发生率分别为24%和35%,髋关节离断分别为4%和10%;高龄与髋关节离断风险升高相关,无补片移植与髋关节离断风险升高相关。
要点
- 全股骨置换术后2年和5年植入物翻修累积发生率分别为24%和35%。
- 全股骨置换术后2年和5年髋关节离断累积发生率分别为4%和10%。
- 高龄与髋关节离断风险升高相关,无补片移植与髋关节离断风险升高相关。
核心结论
- 应告知患者全股骨置换术后翻修发生率高及继发髋关节离断的风险。
- 所识别的风险因素可在患者咨询及手术决策时予以考虑。
- 研究结果证实了补片移植的有益效果。
- 随着截肢患者技术解决方案的进步,应谨慎选择这些复杂重建的适应证,尤其是老年患者。
研究设计与样本
- 本研究为回顾性、多中心欧洲肌肉骨骼肿瘤学会(EMSOS)研究,报告来自14个国际参与中心的数据。
- 研究纳入1990年1月1日至2024年3月31日期间接受全股骨置换的143例患者。
- 患者初次手术时平均±标准差年龄为44±24岁,52%(143例中74例)为男性。
- 大多数患者因肿瘤指征接受全股骨置换(76%[143例中108例];其中12%[108例中13例]接受了可延长生长假体)。
- 在竞争风险框架下分析主要并发症和髋关节离断,以死亡为竞争事件。
主要发现
- 植入物翻修2年累积发生率为24%(95%CI 16%至31%),5年为35%(95%CI 26%至44%)。
- 髋关节离断2年累积发生率为4%(95%CI 1%至7%),5年为10%(95%CI 4%至16%)。
- 高龄与主要并发症风险升高相关(亚分布HR 1.01[95%CI 0.98至1.02];p=0.17,病因特异性HR 1.01[95%CI 1.00至1.03];p=0.023)。
- 高龄与髋关节离断风险升高相关(亚分布HR 1.03[95%CI 1.01至1.05];p<0.001,病因特异性HR 1.05[95%CI 1.02至1.07];p<0.001)。
- 无补片移植与髋关节离断风险升高相关(亚分布HR 0.30[95%CI 0.10至0.92];p=0.035,病因特异性HR 0.46[95%CI 0.15至1.42];p=0.18)。
关键数值与推荐
- 植入物翻修2年累积发生率为24%(95%CI 16%至31%),5年为35%(95%CI 26%至44%)。
- 髋关节离断2年累积发生率为4%(95%CI 1%至7%),5年为10%(95%CI 4%至16%)。
- 高龄与主要并发症风险升高相关(亚分布HR 1.01[95%CI 0.98至1.02];p=0.17,病因特异性HR 1.01[95%CI 1.00至1.03];p=0.023)。
- 高龄与髋关节离断风险升高相关(亚分布HR 1.03[95%CI 1.01至1.05];p<0.001,病因特异性HR 1.05[95%CI 1.02至1.07];p<0.001)。
- 无补片移植与髋关节离断风险升高相关(亚分布HR 0.30[95%CI 0.10至0.92];p=0.035,病因特异性HR 0.46[95%CI 0.15至1.42];p=0.18)。
临床怎么用
- 应告知患者全股骨置换术后翻修发生率高及继发髋关节离断的风险。
- 所识别的风险因素可在患者咨询及手术决策时予以考虑。
- 研究结果证实了补片移植的有益效果。
- 随着截肢患者技术解决方案的进步,应谨慎选择这些复杂重建的适应证,尤其是老年患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Total femur replacements (TFRs) are rarely performed procedures in orthopaedic oncology and revision arthroplasty surgery. These procedures are associated with a high proportion of complications and revisions, most frequently because of infection. Revision risk and associated parameters in a high-risk population remain to be determined. QUESTIONS/PURPOSES: (1) What is the cumulative incidence of implant revision and hip disarticulation after TFR at 2 and 5 years after the index procedure? (2) Which patient-related and procedure-related parameters associate with implant revision and hip disarticulation? (3) What are the overall mortality, oncologic outcome, minor complications, and reoperations in this study population? METHODS: This was a retrospective, multicenter European Musculo-Skeletal Oncology Society (EMSOS) study reporting data from 14 international participating centers. The study included 143 patients who received a TFR between January 1, 1990, and March 31, 2024. The mean ± SD age at index operation was 44 ± 24 years, and 52% (74 of 143) of the participants were men. Most patients underwent TFR for oncologic indications (76% [108 of 143]; 12% [13 of 108] received extendable growth prostheses). Complications, revisions, amputations, as well as clinical and surgical data were documented. We investigated major complications and hip disarticulation in a competing risk framework with death as the competing event. RESULTS: The cumulative incidence of implant revision at 2 and 5 years was 24% (95% confidence interval [CI] 16% to 31%) and 35% (95% CI 26% to 44%). The cumulative incidence of hip disarticulation at 2 and 5 years was 4% (95% CI 1% to 7%) and 10% (95% CI 4% to 16%). We found that advanced patient age was associated with an increased risk for major complications (subdistribution HR 1.01 [95% CI 0.98 to 1.02]; p = 0.17, cause-specific HR 1.01 [95% CI 1.00 to 1.03]; p = 0.023). Furthermore, advanced patient age (subdistribution HR 1.03 [95% CI 1.01 to 1.05]; p < 0.001, cause-specific HR 1.05 [95% CI 1.02 to 1.07]; p < 0.001) and no mesh graft (subdistribution HR 0.30 [95% CI 0.10 to 0.92]; p = 0.035, cause-specific HR 0.46 [95% CI 0.15 to 1.42]; p = 0.18) were associated with higher risk for hip disarticulations. No other risk factor was associated with altered risk for implant revision or hip disarticulation. CONCLUSION: Patients should be informed about the high incidence of revision associated with TFR and the secondary hip disarticulation risk. The identified risk factors may be considered upon patient counseling, as well as for surgical decision-making. Our findings confirm the beneficial effects of mesh grafts. As technical solutions for patients undergoing amputations advance, the indications for these complex reconstructions should be chosen carefully, especially in older patients. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Valentini M, Svehlik M, Leithner A, et al. Which Factors Associate With Implant Revision and Hip Disarticulation After Total Femur Replacement? A Retrospective Multicentric EMSOS Study. Clin Orthop Relat Res. 2026. PMID: 41588606. doi:10.1097/CORR.0000000000003819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。